Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for clinical trials in early 2026.

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 ...

Efimosfermin is a key growth opportunity for GSK with multiple development options and potential first launch in 2029.” GSK indicated that the addition of efimosfermin expands its pipeline for ...

Driven by exceptional growth in Specialty Medicines and Vaccines, GSK’s second-quarter sales reached $10.66 billion (7.98 billion British pounds), a 6% increase at constant currency, exceeding ...

Recent deals include the completed acquisition of efimosfermin, a potential treatment for liver disease, and new partnerships with Hengrui Pharma, aimed at developing up to 12 medicines in ...